Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Metastatic melanoma: MART-1 T-cell receptor modified T-cells

Maartje Rohaan, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, describes the results from the Phase I trial of MART-1 T-cell receptor-modified T-cells in patients with metastatic melanoma and goes on to describe where she sees the field moving in the future. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.